The influence of weight with assay error on gentamicin pharmacokinetics using the Bayesian and nonlinear least square regression analysis in appendicitis patients

The purpose of this study was to determine the influence of weight with gentamicin assay error on the Bayesian and nonlinear least squares regression analysis in 12 Korean appendicitis patients. Gentamicin was administered intravenously over 0.5 h every 8 h. Three specimens were collected 48 h after...

Full description

Saved in:
Bibliographic Details
Published inBiopharmaceutics & drug disposition Vol. 26; no. 5; pp. 189 - 194
Main Author Burm, Jin Pil
Format Journal Article
LanguageEnglish
Published Chichester, UK John Wiley & Sons, Ltd 01.07.2005
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The purpose of this study was to determine the influence of weight with gentamicin assay error on the Bayesian and nonlinear least squares regression analysis in 12 Korean appendicitis patients. Gentamicin was administered intravenously over 0.5 h every 8 h. Three specimens were collected 48 h after the first dose from all patients at the following times, just before the regularly scheduled infusion, at 0.5 h and 2 h after the end of the 0.5 h infusion. Serum gentamicin levels were analysed by fluorescence polarization immunoassay technique with TDxFLx. The standard deviation (SD) of the assay over its working range had been determined at the serum gentamicin concentrations of 0, 2, 4, 8, 12 and 16 µg/ml in quadruplicate. The polynominal equation of gentamicin assay error was found to be SD (µg/ml)=0.0246−(0.0495C)+(0.00203C2). There were differences in the influence of weight with gentamicin assay error on pharmacokinetic parameters of gentamicin using the nonlinear least squares regression analysis but there were no differences on the Bayesian analysis. This polynominal equation can be used to improve the precision of fitting of pharmacokinetic models to optimize the process of model simulation both for population and for individualized pharmacokinetic models. The result would be improved dosage regimens and the better, safer care of patients receiving gentamicin. Copyright © 2005 John Wiley & Sons, Ltd.
Bibliography:ArticleID:BDD450
istex:9D00F89C9767E8B7B0C57FDBB7BF4CC61B3430CF
ark:/67375/WNG-88RS56FQ-T
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0142-2782
1099-081X
DOI:10.1002/bdd.450